false0000917520 0000917520 2020-08-03 2020-08-03


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 29, 2020

INTEGRA LIFESCIENCES HOLDINGS CORPORATION
(Exact name of Registrant as specified in its charter)

Delaware
0-26224
51-0317849
(State or other jurisdiction of incorporation or organization)
(Commission File Number)
(I.R.S. Employer Identification No.)

1100 Campus Road
Princeton, NJ 08540
(Address of principal executive offices) (Zip Code)
 
Registrant's telephone number, including area code: (609) 275-0500

Not Applicable
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities Registered Pursuant to Section12(b) of the Act:
Title of Each Class
Trading Symbol
Name of Exchange on Which Registered
Common Stock, Par Value $.01 Per Share
IART
Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  





Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Revocation of Temporary Reduction in Base Salary of Executive Officers
 
On April 16, 2020, the Compensation Committee (the “Committee”) of the Company’s Board of Directors (the “Board”) and the Board approved temporary reductions in the base salaries of the Company’s named executive officers in response to uncertainty caused by the COVID-19 pandemic. On July 29, 2020, the Board and the Committee approved the revocation of those temporary base salary reductions, effective August 1, 2020. As a result, on August 1, 2020, the base salaries of Peter J. Arduini, the Company’s President and Chief Executive Officer; Carrie Anderson, the Chief Financial Officer; Glenn Coleman, the Chief Operating Officer; Robert Davis, President of Orthopedics and Tissue Technologies; and Eric Schwartz, the Chief Legal Officer will be restored to the amounts in effect immediately prior to the implementation of the temporary decreases.








SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


 
INTEGRA LIFESCIENCES HOLDINGS CORPORATION
 
 
 
Date: August 3, 2020
By:
 /s/ Carrie Anderson
 
 
Carrie Anderson
 
Title:
Executive Vice President and Chief Financial Officer